title: Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly.
abstract: BACKGROUND
  The effects of GH replacement in GH-deficient (GHD) adults previously treated for acromegaly are not well known. OBJECTIVE, DESIGN, AND PATIENTS: In this single-center, open-labeled, prospective study, 10 consecutive GHD adults with cured acromegaly (A group) and 10 matched GHD adults with previous nonfunctioning hypopituitary disease (NF group) were included. Comparisons were made at baseline and in the responses in body composition, muscle strength, bone mass, and metabolic indices during 2 yr of GH replacement.
  
  
  RESULTS
  At baseline, upper leg local muscle endurance and serum low-density lipoprotein-cholesterol concentration were more impaired in the A group. The A group contained three patients with hypertension, one with diabetes mellitus type 2, and one with hyperlipidemia. The NF group had only one patient with hypertension. There were no significant between-group differences in the responses to the GH therapy. Body composition and serum lipid pattern improved in both groups without any deterioration of glucose homeostasis. At study end, no difference remained between the two groups in any variable. During the 2-yr treatment, one patient had a myocardial infarction and two had cerebral infarctions in the A group, whereas no vascular event occurred in the NF group.
  
  
  CONCLUSIONS
  GHD patients with previous acromegaly have an impaired cardiovascular risk profile and decreased local muscle endurance as compared with other GHD patients. Two-year GH replacement eliminated these differences, but vascular events occurred more frequently in the A group. Therefore, GHD patients with cured acromegaly will benefit from GH replacement, but careful monitoring of cardiovascular status is needed.
authors.affiliation: Research Centre for Endocrinology and Metabolism, Department of Internal Medicine, Gröna Stråket 8, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: Lise-Lott
authors.initials: LL
authors.lastname: Norrman
authors.forename: Gudmundur
authors.initials: G
authors.lastname: Johannsson
authors.forename: Katharina S
authors.initials: KS
authors.lastname: Sunnerhagen
authors.forename: Johan
authors.initials: J
authors.lastname: Svensson
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D001794:Blood Pressure; D001823:Body Composition; D015519:Bone Density; D008078:Cholesterol, LDL / Q000097:blood; D005947:Glucose / Q000378:metabolism; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D050356:Lipid Metabolism; D053580:Muscle Strength; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D008078:Cholesterol, LDL; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D005947:Glucose